News
CUE
1.140
+3.64%
0.040
Weekly Report: what happened at CUE last week (1202-1206)?
Weekly Report · 2d ago
Weekly Report: what happened at CUE last week (1125-1129)?
Weekly Report · 12/02 11:06
CUE BIOPHARMA REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 11/29 21:30
Cue Biopharma to Present at Piper Sandler 36th Annual Healthcare Conference on Clinical and Strategic Updates
Barchart · 11/25 17:20
Weekly Report: what happened at CUE last week (1118-1122)?
Weekly Report · 11/25 10:58
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
Barchart · 11/25 07:00
Weekly Report: what happened at CUE last week (1111-1115)?
Weekly Report · 11/18 10:56
Analysts Are Bullish on These Healthcare Stocks: Hookipa Pharma (HOOK), Cue Biopharma (CUE)
TipRanks · 11/18 05:40
Cue Biopharma’s Nasdaq Compliance Struggle: Risks and Implications for Future Stability
TipRanks · 11/16 06:00
CUE BIOPHARMA INC <CUE.O>: JEFFERIES CUTS TARGET PRICE TO $4 FROM $6
Reuters · 11/15 14:17
Cue Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters · 11/15 14:10
Stifel Nicolaus Remains a Buy on Cue Biopharma (CUE)
TipRanks · 11/15 13:15
Cue Biopharma GAAP EPS of -$0.17 beats by $0.02, revenue of $3.34M beats by $1.82M
Seeking Alpha · 11/15 10:06
U.S. RESEARCH ROUNDUP-Applied Materials, Disney, Walmart
Reuters · 11/15 06:42
Cue Biopharma Reports Increased Revenue Amid Ongoing Losses
TipRanks · 11/15 04:34
Cue Biopharma, Inc. Reports Third Quarter 2024 Business and Financial Update, Highlighting Positive Phase 1 Trial Data for CUE-101 and CUE-102
Barchart · 11/15 01:20
Cue Biopharma, Inc. Reports Financial Results for the Quarter Ended September 30, 2024
Press release · 11/14 23:39
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 11/14 22:25
Cue Biopharma Q3 2024 GAAP EPS $(0.17) Beats $(0.19) Estimate, Sales $3.336M Beat $1.520M Estimate
Benzinga · 11/14 21:43
Cue Biopharma reports Q3 EPS (17c), consensus (19c)
TipRanks · 11/14 21:25
More
Webull provides a variety of real-time CUE stock news. You can receive the latest news about Cue Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.